BioMedNewsBreaks

MondayOct 24, 2022 1:02 pm

BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Distinctive with Ground-Breaking Research, Commitment to Developing Innovative Solutions

Silo Pharma (NASDAQ: SILO) recently uplisted to the NASDAQ after the exciting progress it made over the last year. “Silo Pharma announced that it had successfully priced its fully underwritten initial public offering, raising gross proceeds of $5 million through the sale of one million shares of common stock,” reads a recent article. “Originally founded in 2010, Silo Pharma has distinguished itself amongst peers for its ground-breaking research into conditions such as post-traumatic stress disorder (‘PTSD’), fibromyalgia, Alzheimer’s, Parkinson’s, and other rare neurological disorders. Increasingly and over the past two decades, clinical research on psychedelics, most notably psilocybin and methylenedioxymethamphetamine…

Continue Reading

FridayOct 21, 2022 3:05 pm

BioMedNewsBreaks – HeartBeam Inc.’s (NASDAQ: BEAT) Patented Breakthrough Technology Poised to Disrupt ECG Patch Market

HeartBeam (NASDAQ: BEAT) recently received a patent from the United States Patent and Trademark Office for its 12-lead electrocardiogram (“ECG”) patch monitor for the detection of acute coronary syndrome (“ACS”) and cardiac arrhythmia. “The new patent expands on a previously granted patent for a 12-lead ECG patch monitor technology. HeartBeam noted that the patent opens a pathway to a disruptive ischemia and arrhythmia detection ECG patch product. In addition, the innovation builds on HeartBeam’s growing intellectual property portfolio that could enable 12-lead ECG diagnostics outside of a medical setting… Currently, the ECG patch monitor market is limited to detecting arrhythmias…

Continue Reading

FridayOct 21, 2022 2:09 pm

BioMedNewsBreaks – IBN, InvestorWire to Expand Virtual Presence of Octane’s Medical Innovation Forum

IBN (“InvestorBrandNetwork”), an innovative corporate communications firm and content distributor, today announced that it will serve as an official media partner for Octane’s upcoming Medical Innovation Forum. In addition, IBN’s InvestorWire (“IW”) brand was engaged as the official newswire for the event. Slated to be held in a hybrid format on Oct. 27-28, 2022, attendees will be able to participate virtually as well as on-site at the Irvine Marriott in Irvine, California. Octane’s mission is to enable a broader business ecosystem in Southern California, facilitating tech and medtech ventures to flourish with a target of generating more than 55,000 high-paying technology jobs in the…

Continue Reading

FridayOct 21, 2022 11:54 am

BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Announces Key Milestone in Advancing Adimune(TM) Program

Aditxt (NASDAQ: ADTX) is a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system. The company today announced that its program Adimune(TM) has initiated the GMP manufacturing of drug candidate ADI(TM)-100 as a key milestone toward its goal to begin first-in-human trials during the second half of 2023. Pending regulatory approvals, the trials will be performed in autoimmune diseases, first studying psoriasis. Dr. Joachim-Friedrich Kapp, M.D., Ph.D., a 30-year veteran of the pharmaceutical industry and former president of multinational pharmaceutical company Schering AG’s therapeutics business unit, is leading Adimune’s(TM) ADI(TM) immune modulation…

Continue Reading

ThursdayOct 20, 2022 1:24 pm

BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Data Supporting SPC-14’s Therapeutic Potential for Alzheimer’s

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced proof-of-concept data supporting the therapeutic potential of SPC-14 as a treatment for Alzheimer’s disease, as demonstrated in a mouse model. According to the announcement, the research was conducted as part of a sponsored agreement with Columbia University in New York. “The result from these studies is a first step in the development of SPC-14 as a potential therapeutic for the treatment of Alzheimer’s,” said Silo Pharma CEO Eric Weisblum. “SPC-14 is a therapeutic that utilizes ketamine as one part of the…

Continue Reading

ThursdayOct 20, 2022 8:45 am

BioMedNewsBreaks – MetAlert Inc. (MLRT) Announces Completion of Corporate Actions, Engagement of North Equities Corp for Digital Marketing Expertise

MetAlert (OTC: MLRT), a pioneer in the field of health and safety, wearable GPS human and asset tracking systems, today announced its receipt of final approval from the regulatory bodies and completion of all corporate actions filed in the 14c on July 19. Formerly known as GTX Corp, MetAlert Inc. is now operating and trading under its new ticker symbol MLRT. In addition, as part of its marketing strategy, MetAlert retained North Equities Corp to provide digital marketing services aimed at building awareness of its rebranding and positioning in the medical device, telehealth and remote patient monitoring (“RPM”) industry. “We…

Continue Reading

WednesdayOct 19, 2022 9:30 am

BioMedNewsBreaks – MetAlert Inc. (MLRT) Featured on Stock Day Podcast

MetAlert (OTC: MLRT), a pioneer in smart, mobile and wearable tracking and recovery location-based solutions, was featured on a recent episode of the Stock Day Podcast. MetAlert’s CEO Patrick Bertagna joined Stock Day host Everett Jolly to discuss the company’s background, current projects and focus. “We have expanded the capabilities of our SmartSole(R) platform. We have added Bluetooth, WI-FI and sensors inside of the hardware platform, which will allow us to monitor not just where someone is but also how they are doing... We are also going to be adding products that monitor how people are doing at home... On…

Continue Reading

TuesdayOct 18, 2022 1:01 pm

BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Agreement with Columbia University to Extend Research Pact

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, has entered into an agreement with Columbia University to extend its current research partnership efforts. The agreement outlines certain assets that are currently under development regarding the work of associate professor of clinical Neurobiology Dr. Christine Ann Denny at Columbia University Irving Medical Center. Denny and her team are studying the molecular mechanisms underlying learning and memory, including diseases such as Alzheimer’s disease. According to the announcement, Denny’s pioneering research is evaluating whether ketamine and novel inventions associated with the substance have potential…

Continue Reading

MondayOct 17, 2022 2:35 pm

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Featured in BioWorld(TM) MedTech Article

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed an innovative platform for heart attack detection anytime, anywhere, was featured in a recent BioWorld(TM) MedTech article. “HeartBeam Inc. has been awarded a patent for what it called ‘the first and only’ 3D-vector, 12-lead ECG platform for heart attack detection, this in conjunction with a credit card-sized device inside a consumer’s wallet for personal monitoring,” the piece reads. “The company said it can record and remotely transmit a set of cardiac signals to a physician for review so that patients at high risk of cardiac arrest are not left alone…

Continue Reading

MondayOct 17, 2022 1:36 pm

BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Continues Focus to Create the Best Psychedelic Therapies for Patients

Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions, is conducting a phase 1/2a trial evaluating CYB003, its lead investigational molecule and the first-ever novel psilocybin analog to enter clinical development. “The in-human trial is critical to the company’s continued development of CYB003, a deuterated psilocybin analog that Cybin believes has potential to successfully address the challenges and limitations of oral psilocybin. According to the company’s preclinical research, CYB003 achieved less variability in plasma levels, along with faster onset of action, improved brain penetration, and shorter duration…

Continue Reading